Case-control study, 2024
Do women with PMDD have permanent differences in brain structure?
Yes. Women with PMDD have thinner brain surface and lower folding patterns than women without PMDD, regardless of menstrual cycle phase. This suggests these are stable features of PMDD, not just temporary changes.
What they did
Women with PMDD and healthy controls had MRI brain scans during two menstrual cycle phases: mid-follicular and late-luteal. Researchers measured cortical thickness, gyrification (brain folding), cortical complexity, and sulcal depth.
What they found
Regardless of menstrual cycle phase, women with PMDD showed thinner cortex (0.3 to 1.1) and lower gyrification (0.4 to 1.0) than controls. All participants showed decreased cortical thickness (0.4 to 1.7) from the mid-follicular to late-luteal phase. Menstrual cycle-specific changes in cortical folding (0.4 to 2.2) were observed in both groups.
What it means for you
PMDD may involve stable brain structure differences that exist regardless of cycle phase, suggesting permanent rather than temporary changes. The effect sizes were small and larger studies are needed to understand whether these are stable markers or develop over time.
0.3-1.1
Cortical thickness in PMDD
0.4-1.0
Gyrification in PMDD
0.4-2.2
Brain folding variation across cycle
About the study
- Original title
- Cortical morphology variations during the menstrual cycle in individuals with and without premenstrual dysphoric disorder
- Authors
- Dubol M, Stiernman L, Sundström-Poromaa I et al.
- Journal
- Journal of affective disorders
- Year
- 2024
- Study design
- Case-control study
- What was tested
- Structural brain imaging at two menstrual cycle phases
- Open access
- Yes
- Read the paper
- doi.org/10.1016/j.jad.2024.03.130
Original abstract
Background: Premenstrual dysphoric disorder (PMDD) is hypothesized to stem from maladaptive neural sensitivity to ovarian steroid hormone fluctuations. Recently, we found thinner cortices in individuals with PMDD, compared to healthy controls, during the symptomatic phase. Here, we aimed at investigating whether such differences illustrate state-like characteristics specific to the symptomatic phase, or trait-like features defining PMDD. Methods: Patients and controls were scanned using structural magnetic resonance imaging during the mid-follicular and late-luteal phase of the menstrual cycle. Group-by-phase interaction effects on cortical architecture metrics (cortical thickness, gyrification index, cortical complexity, and sulcal depth) were assessed using surface-based morphometry. Results: Independently of menstrual cycle phase, a main effect of diagnostic group on surface metrics was found, primarily illustrating thinner cortices (0.3 1.1) and lower gyrification indices (0.4 1.0) in patients compared to controls. Furthermore, menstrual cycle-specific effects were detected across all participants, depicting a decrease in cortical thickness (0.4 1.7) and region-dependent changes in cortical folding metrics (0.4 2.2) from the mid-follicular to the late luteal phase. Limitations: Small effects (d = 0.3) require a larger sample size to be accurately characterized. Conclusions: These findings provide initial evidence of trait-like cortical characteristics of the brain of individuals with premenstrual dysphoric disorder, together with indications of menstrual cycle-related variations in cortical architecture in patients and controls. Further investigations exploring whether these differences constitute stable vulnerability markers or develop over the years may help understand PMDD etiology.
Reproduced under CC-BY.
Topics
Related studies
Cohort study, 2026
What genetic factors are linked to premenstrual symptoms?
Systematic review, 2026
How often do mood disorders and PMS or PMDD occur together?
Systematic review, 2026
Does vitamin D supplementation help PMS symptoms?
Study, 2026
How do women with PMDD process emotions differently in their brains?
Systematic review, 2026
Why do some women experience mood changes linked to their menstrual cycle?
Systematic review, 2026
How much of PMDD treatment improvement comes from placebo effect?